X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/12/13/2795215/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ELUNATE-fruquintinib-and-SULANDA-surufatinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html
https://www.biopharmadive.com/news/fda-reject-hutchmed-junshi-china-developed-cancer-drug/623024/
https://www.globenewswire.com/news-release/2021/09/21/2300172/0/en/HUTCHMED-Initiates-SURTORI-01-a-Phase-III-Trial-of-SULANDA-in-Combination-with-TUOYI-in-the-Treatment-of-Advanced-Neuroendocrine-Carcinoma-in-China.html
https://www.globenewswire.com/news-release/2021/07/01/2256328/0/en/U-S-FDA-Accepts-Filing-of-HUTCHMED-s-NDA-for-Surufatinib-for-the-Treatment-of-Advanced-Neuroendocrine-Tumors.html
https://www.globenewswire.com/news-release/2021/06/18/2249756/0/en/HUTCHMED-Announces-NMPA-Approval-of-Surufatinib-Sulanda-in-China-for-Advanced-Pancreatic-Neuroendocrine-Tumors.html
https://www.chi-med.com/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet/#:~:text=30%20Dec%202020-,Chi%2DMed%20Announces%20the%20NMPA%20Approval%20of%20Surufatinib%20(Sulanda%C2%AE,for%20Non%2DPancreatic%20Neuroendocrine%20Tumors&text=If%20our%20second%20new%20drug,regardless%20of%20the%20tumor%20origin.%E2%80%9D
https://www.onclive.com/view/rolling-submission-for-surufatinib-started-for-advanced-neuroendocrine-tumors
https://www.onclive.com/view/rolling-submission-for-surufatinib-started-for-advanced-neuroendocrine-tumors
https://endpts.com/with-plans-to-bring-surufatinib-stateside-chi-med-vastly-scales-up-manufacturing-with-new-chinese-plant/
https://www.esmo.org/meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter-news/surufatinib-potential-new-option-advanced-pancreatic-nets
https://www.globenewswire.com/news-release/2020/09/20/2096198/0/en/Chi-Med-Highlights-Surufatinib-Phase-III-Results-in-Neuroendocrine-Tumors-at-ESMO-2020-and-Publications-in-The-Lancet-Oncology.html
https://www.chi-med.com/chi-med-highlights-clinical-data-to-be-presented-at-the-upcoming-esmo-virtual-congress-2020/
https://www.chi-med.com/chi-med-plans-to-submit-maa-for-surufatinib/
https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-a-phase-1b-clinical-trial-of-sintilimab-plus-surufatinib-in-advanced-malignancies-in-china-301090080.html#:~:text=(%22Innovent%22)%20(HKEX,a%20Phase%201b%20clinical%20trial%20(
https://www.globenewswire.com/news-release/2020/04/22/2019761/0/en/Chi-Med-Highlights-Presentations-of-Surufatinib-at-the-Upcoming-AACR-Virtual-Annual-Meetings.html
http://www.pharmatimes.com/news/chi-med_surufatinib_bags_us_fast_track_designations_1338490
http://www.news-medical.net/news/20151106/Hutchison-MediPharma-begins-sulfatinib-Phase-I-trial-in-US.aspx?
Market Place
Share 
